Danaher Co. (NYSE:DHR) Shares Sold by MCF Advisors LLC

MCF Advisors LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 8.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 573 shares of the conglomerate’s stock after selling 54 shares during the quarter. MCF Advisors LLC’s holdings in Danaher were worth $143,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of DHR. Tsfg LLC increased its stake in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the period. Cape Investment Advisory Inc. purchased a new stake in Danaher in the fourth quarter valued at $25,000. BKM Wealth Management LLC acquired a new stake in Danaher during the 4th quarter worth about $27,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher during the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. acquired a new position in shares of Danaher in the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the subject of several recent research reports. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and lifted their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Jefferies Financial Group assumed coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. TD Cowen increased their target price on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Barclays lifted their price target on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 148,783 shares of company stock worth $37,536,717. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Down 0.7 %

NYSE DHR opened at $249.85 on Friday. The business has a fifty day moving average price of $255.96 and a 200 day moving average price of $246.61. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company has a market cap of $185.06 billion, a P/E ratio of 42.35, a P/E/G ratio of 3.82 and a beta of 0.85. Danaher Co. has a one year low of $182.09 and a one year high of $269.11.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.36 earnings per share. Research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.